McKesson Corporation
$1,069.43+$7.27 (+0.7%)
Last close · Data as of Nov 20, 2026
- Market cap
- $91.0B
- P/E
- 19.1x
- EV / EBITDA
- 13.3x
- Revenue
- $403.4B
- Net margin
- 1.2%
- ROCE
- 42.2%
Price chart
Technical chartScreen technicals →+25.9% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- +3.8%
- 3M
- +27.5%
- 6M
- +41.7%
- 1Y
- +25.9%
- 5Y
- +384.1%
52-week range
Day change +$7.27 (+0.7%) from $1,062 to $1,069 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in MCK, bought on each weekday since 2021.
News & filings
What McKesson filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernShareholders' equity is negative: liabilities exceed assets.
Strengths (1)
- Return on capital employed of 42.2%.
- Shareholders' equity is negative, so return on equity and debt to equity are not shown.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2026
Rule-based from financial data. Not advice.
About the company
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.
Read moreShow less
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The RxTS segment serves biopharma and life sciences partners to address challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver solutions to help people get the medicine needed to live healthier lives; and provides medication access and affordability, prescription decision support, prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services, as well as electronic prior authorization services. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, biomedical maintenance, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, post-acute care facilities, hospital reference labs, and home health care agencies. The International segment delivers medicines, supplies, and information technology solutions to retail pharmacies, hospitals, long-term care centers, clinics and institutions; and provides logistics and distribution services for manufacturers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
- Sector
- Healthcare
- Shares outstanding
- 123.5M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $91.0B
- P/E
- 19.1x
- P/B
- -41.9x
- EV / EBITDA
- 13.3x
- EV / Sales
- 0.2x
- P/S
- 0.2x
- 52-week high
- $1,105.04
- 52-week low
- $725.17
Profitability
- Operating margin
- 1.6%
- Net margin
- 1.2%
- EBITDA margin
- 1.8%
- ROE
- -219.2%
- ROCE
- 42.2%
- ROA
- 5.8%
- Asset turnover
- 4.90
Growth
- RevenueFY2026, the latest fiscal year in the company's growth history.
- $403.4B
- Revenue growth, 1YFY2026, the latest fiscal year in the company's growth history.
- 12.4%
- Revenue CAGR, 3YFY2026, the latest fiscal year in the company's growth history.
- 13.4%
- Net profit growth, 1YFY2026, the latest fiscal year in the company's growth history.
- 44.5%
- Free cash flowFY2026, the latest fiscal year in the company's growth history.
- $5.4B
Solvency
- Current ratio
- 0.85
- Debt / Equity
- -3.97
- Debt / Assets
- 0.10
- CFO / Net profit
- 1.29
- Cash / Market cap
- 4.4%
Where the revenue went
Of every $100 of FY2026 revenue, $1 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $388.9B |
| Revenue | Gross profit | $14.6B |
| Gross profit | Selling, general and administrative | $8.1B |
| Gross profit | Operating income | $6.5B |
| Operating income | Pretax income | $6.2B |
| Operating income | Interest and other expense | $253.0M |
| Pretax income | Tax and other | $1.4B |
| Pretax income | Net income | $4.8B |
Revenue and net profit
Revenue grew 12.4% in FY2026; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2023 | $276.7B | $3.6B |
| FY2024 | $309.0B | $3.0B |
| FY2025 | $359.1B | $3.3B |
| FY2026 | $403.4B | $4.8B |
Cash flows
FY2026: $6.2B from operations, $5.4B free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2023 | $5.2B | $4.6B |
| FY2024 | $4.3B | $3.6B |
| FY2025 | $6.1B | $5.2B |
| FY2026 | $6.2B | $5.4B |
Growth
Latest fiscal year 2026: each figure with its change over the year before.
- Revenue
- $403.4B+12.4%1Y
- EBITDA
- $7.2B+36.4%1Y
- Net profit
- $4.8B+44.5%1Y
- Cash from operations
- $6.2B+1.2%1Y
- Free cash flow
- $5.4B+3.5%1Y
- Revenue CAGR, 3Y
- 13.4%
- Net profit CAGR, 3Y
- 10.2%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2026 | $403.4B | $7.2B | $4.8B | $5.4B | -219.2% | +12.4% | +44.5% |
Monthly returns
Month-by-month returns of MCK across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2026.
| Line | FY2026 |
|---|---|
| Assets | $82.3B |
| Current assets | $57.2B |
| Non-current assets | $25.1B |
| Liabilities | $83.2B |
| Current liabilities | $67.0B |
| Non-current liabilities | $16.1B |
| Equity | -$834.0M |
| Paid-in capital | $8.3B |
| Retained earnings | $22.3B |
| Treasury stock | $32.0B |
| Minority interest | $1.3B |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; MCK highlighted.
P/E against peers
MCK trades at 19.1x earnings against a peer median of 19.5x.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| McKesson CorporationMCKthis company | $91.0B | 19.1x | -41.9x | -219.2% | 13.3x |
| Bristol-Myers Squibb CompanyBMY | $115.6B | 16.4x | 6.3x | 38.2% | 10.0x |
| Stryker CorporationSYK | $115.5B | 35.6x | 5.2x | 14.5% | 20.2x |
| Vertex Pharmaceuticals IncorporatedVRTX | $112.1B | 28.4x | 6.0x | 21.2% | 22.4x |
| Medtronic plcMDT | $105.2B | 22.6x | 2.2x | 9.7% | 14.3x |
| Elevance Health, Inc.ELV | $88.9B | 15.7x | 2.0x | 12.9% | — |
| HCA Healthcare, Inc.HCA | $80.3B | 11.8x | -13.3x | -112.6% | 8.2x |
| The Cigna GroupCI | $74.2B | 12.5x | 1.8x | 14.3% | 10.2x |
| Boston Scientific CorporationBSX | $72.6B | 25.1x | 3.0x | 12.0% | 16.1x |
| Peer median | — | 19.5x | 2.6x | 13.6% | 14.3x |
Year-to-date ROI
MCK since 1 January, against earlier years.
Historical volatility
MCK's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2023 | 1.7% |
| FY2024 | 1.4% |
| FY2025 | 1.3% |
| FY2026 | 1.6% |
| Line | FY2026 |
|---|---|
| RevenueTotal Revenue | $403.4B |
| Cost of revenueCost Of Revenue | $388.9B |
| Gross profitGross Profit | $14.6B |
| Operating expensesOperating Expense | $8.1B |
| Selling, general and administrativeSelling General And Administration | $8.1B |
| Total expensesTotal Expenses | $397.0B |
| Operating incomeOperating Income | $6.5B |
| Interest and other | |
| Pretax incomePretax Income | $6.2B |
| TaxTax Provision | $1.1B |
| Net incomeNet Income | $4.8B |
| Per share | |
| Supplementary |
| Line | FY2026 |
|---|---|
| AssetsTotal Assets | $82.3B |
| Current assetsCurrent Assets | $57.2B |
| Non-current assetsTotal Non Current Assets | $25.1B |
| LiabilitiesTotal Liabilities Net Minority Interest | $83.2B |
| Current liabilitiesCurrent Liabilities | $67.0B |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $16.1B |
| EquityTotal Equity Gross Minority Interest | -$834.0M |
| Supplementary |
| Line | FY2026 |
|---|---|
| Operating cash flowOperating Cash Flow | $6.2B |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $6.2B |
| Net income, continuing operationsNet Income From Continuing Operations | $5.1B |
| Depreciation and amortisationDepreciation And Amortization | $729.0M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $729.0M |
| Depreciation | $256.0M |
| Amortization cash flowAmortization Cash Flow | $473.0M |
| Amortization of intangiblesAmortization Of Intangibles | $473.0M |
| Deferred taxDeferred Tax | $230.0M |
| Deferred income taxDeferred Income Tax | $230.0M |
| Operating gains and lossesOperating Gains Losses | -$573.0M |
| Gain loss on sale of businessGain Loss On Sale Of Business | -$573.0M |
| Earnings losses from equity investmentsEarnings Losses From Equity Investments | — |
| Asset impairmentAsset Impairment Charge | $55.0M |
| Provision and write off of assetsProvisionand Write Offof Assets | $100.0M |
| Change in working capitalChange In Working Capital | -$57.0M |
| Other non-cash itemsOther Non Cash Items | $572.0M |
| Investing cash flowInvesting Cash Flow | -$3.4B |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$3.4B |
| Capital expenditureCapital Expenditure | -$745.0M |
| Capital expenditure (reported)Capital Expenditure Reported | -$309.0M |
| Purchase of PP&EPurchase Of PPE | -$436.0M |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$436.0M |
| AcquisitionsPurchase Of Business | -$3.4B |
| DisposalsSale Of Business | $830.0M |
| Net acquisitions and disposalsNet Business Purchase And Sale | -$2.6B |
| Other investing changesNet Other Investing Changes | -$101.0M |
| Financing cash flowFinancing Cash Flow | -$4.6B |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$4.6B |
| Debt issuedIssuance Of Debt | $11.2B |
| Debt repaidRepayment Of Debt | -$10.5B |
| Net debt issuedNet Issuance Payments Of Debt | $783.0M |
| Short-term debt issuedShort Term Debt Issuance | $9.2B |
| Short-term debt repaidShort Term Debt Payments | -$9.2B |
| Net short-term debt issuedNet Short Term Debt Issuance | $0.00 |
| Long-term debt issuedLong Term Debt Issuance | $2.0B |
| Long-term debt repaidLong Term Debt Payments | -$1.2B |
| Net long-term debt issuedNet Long Term Debt Issuance | $783.0M |
| Shares issuedIssuance Of Capital Stock | $89.0M |
| Common stock issuedCommon Stock Issuance | $89.0M |
| Net common stock issuedNet Common Stock Issuance | -$4.7B |
| Common stock repurchasedCommon Stock Payments | -$4.8B |
| Share buybacksRepurchase Of Capital Stock | -$4.8B |
| Dividends paidCash Dividends Paid | -$381.0M |
| Common dividends paidCommon Stock Dividend Paid | -$381.0M |
| Other financing chargesNet Other Financing Charges | -$372.0M |
| Change in cashChanges In Cash | -$1.9B |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 2,000.0% |
| Other cash adjustment inside change in cashOther Cash Adjustment Inside Changein Cash | — |
| Other cash adjustment outside change in cashOther Cash Adjustment Outside Changein Cash | -$93.0M |
| Cash at the start of the yearBeginning Cash Position | $6.0B |
| Cash at the end of the yearEnd Cash Position | $4.0B |
| Free cash flowFree Cash Flow | $5.4B |
| Supplemental |
Learn while you research
Academy chapters picked for McKesson Corporation and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read